Back to Search Start Over

Algorithm for Rapid Exclusion of Clinically Relevant Plasma Levels of Direct Oral Anticoagulants in Patients Using the DOAC Dipstick: An Expert Consensus Paper.

Authors :
Harenberg J
Gosselin RC
Cuker A
Becattini C
Pabinger I
Poli S
Weitz J
Ageno W
Bauersachs R
Celap I
Choi P
Douketis J
Douxfils J
Elalamy I
Falanga A
Fareed J
Favaloro EJ
Gerotziafas G
Herkner H
Hetjens S
Heubner L
Klamroth R
Langer F
Lip GYH
Grory BM
Margetić S
Merrelaar A
Pikta M
Renne T
Schulman S
Schwameis M
Strbian D
Tafur A
Vassart J
Violi F
Walenga J
Weiss C
Source :
Thrombosis and haemostasis [Thromb Haemost] 2024 Aug; Vol. 124 (8), pp. 770-777. Date of Electronic Publication: 2024 Feb 05.
Publication Year :
2024

Abstract

Background:  With the widespread use of direct oral anticoagulants (DOACs), there is an urgent need for a rapid assay to exclude clinically relevant plasma levels. Accurate and rapid determination of DOAC levels would guide medical decision-making to (1) determine the potential contribution of the DOAC to spontaneous or trauma-induced hemorrhage; (2) identify appropriate candidates for reversal, or (3) optimize the timing of urgent surgery or intervention.<br />Methods and Results:  The DOAC Dipstick test uses a disposable strip to identify factor Xa- or thrombin inhibitors in a urine sample. Based on the results of a systematic literature search followed by an analysis of a simple pooling of five retrieved clinical studies, the test strip has a high sensitivity and an acceptably high negative predictive value when compared with levels measured with liquid chromatography tandem mass spectrometry or calibrated chromogenic assays to reliably exclude plasma DOAC concentrations ≥30 ng/mL.<br />Conclusion:  Based on these data, a simple algorithm is proposed to enhance medical decision-making in acute care indications useful primarily in hospitals not having readily available quantitative tests and 24/7. This algorithm not only determines DOAC exposure but also differentiates between factor Xa and thrombin inhibitors to better guide clinical management.<br />Competing Interests: J.H. is general manager and founder of DOASENSE GmbH, J.D. is CEO of Qualiblood SA. All other authors declare no conflicts of interest.<br /> (Thieme. All rights reserved.)

Details

Language :
English
ISSN :
2567-689X
Volume :
124
Issue :
8
Database :
MEDLINE
Journal :
Thrombosis and haemostasis
Publication Type :
Academic Journal
Accession number :
38316416
Full Text :
https://doi.org/10.1055/a-2261-1811